AG-1478 (Tyrphostin AG-1478)

For research use only. Not for use in humans.

目录号:S2728 别名: NSC 693255

AG-1478 (Tyrphostin AG-1478) Chemical Structure

CAS No. 153436-53-4

AG-1478 (Tyrphostin AG-1478, NSC 693255) 是一种选择性EGFR抑制剂,在无细胞试验中IC50为3 nM,对HER2-Neu,PDGFR,Trk,Bcr-Abl和InsR几乎没有作用活性。AG-1478(Tyrphostin AG-1478)通过靶向 phosphatidylinositol 4-kinase IIIα (PI4KA) 抑制脑心肌炎病毒encephalomyocarditis virus (EMCV)和丙型肝炎病毒hepatitis c virus (HCV)

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 647.01 现货
RMB 568.51 现货
RMB 901.14 现货
RMB 1805.36 现货
RMB 3037.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的AG-1478 (Tyrphostin AG-1478)发表文献69篇:

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述 AG-1478 (Tyrphostin AG-1478, NSC 693255) 是一种选择性EGFR抑制剂,在无细胞试验中IC50为3 nM,对HER2-Neu,PDGFR,Trk,Bcr-Abl和InsR几乎没有作用活性。AG-1478(Tyrphostin AG-1478)通过靶向 phosphatidylinositol 4-kinase IIIα (PI4KA) 抑制脑心肌炎病毒encephalomyocarditis virus (EMCV)和丙型肝炎病毒hepatitis c virus (HCV)
靶点
EGFR [1]
(Cell-free assay)
3 nM
体外研究

AG-1478作用于ErbB2和PDGFR 的选择性较差,IC50为>100 μM。[1]与表达内源性wt EGFR或过表达外源性wt EGFR的细胞(IC50分别为34.6 μM和48.4 μM)相比,AG-1478优先抑制表达ΔEGFR的U87MG细胞,IC50为8.7 μM,并且抑制DNA合成,IC50分别为4.6 μM,19.67 μM,和35.2 μM。与内源性或过表达的外源性wt EGFR 相比,AG-1478也会优先抑制酪氨酸激酶活性和ΔEGFR的自身磷酸化。[2] 在VSMC 中,AG-1478 (0.25 μM)废止Ang II,Ca2+离子载体以及EGF诱导的MAPK活化,但是不影响佛波酯或血小板源生长因子-BB诱导的MAPK活化。[3] AG-1478抑制EGF诱导的BaF/ERX和LIM1215细胞中有丝分裂,IC50分别为0.07 μM 和 0.2 μM。[6] AG1478能够抑制ATP-结合盒(ABC)转运蛋白的功能,比如ABCB1和ABCG2,对ABCG2具有明显的作用。[7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U87MG NHLlOWZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX3+NVAxKM7:TR?= M2LDXGROW09? MWfJR|UxRTN2Lk[g{txO MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek85PzV{MUS1K|45PzV{MUS1QE9iRg>?
U87MG.ΔEGFR NHnLXHdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHq4[Xd,OTByIN88US=> MWLEUXNQ MXvJR|UxRThwNzFOwG0> M4fCXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzh5NUKxOFUoRjh5NUKxOFU9N2F-
U87MG.wtEGFR. MoHjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmP3glExOCEQvF2= NWXQ[3JRTE2VTx?= MVjJR|UxRTR6LkSg{txO Mn;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQDd3MkG0OUc,QDd3MkG0OVww[T5?
U87MG MmHOT4lv[XOnIHHzd4F6 NES0VZF,OTByIN88US=> MYfEUXNQ NGD0VFlqdmirYnn0d{BGT0[UIIT5do9{cW6nIHvpcoF{\SCjY4Tpeol1gQ>? NIGzOWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96N{WyNVQ2Lz56N{WyNVQ2RC:jPh?=
U87MG.ΔEGFR MmLST4lv[XOnIHHzd4F6 M4\jbZ4yODBizszN NUHrOmc6TE2VTx?= M1PNeolvcGmkaYTzJGVITlJidInyc5NqdmVia3nuZZNmKGGldHn2bZR6 NES5N|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96N{WyNVQ2Lz56N{WyNVQ2RC:jPh?=
U87MG.wtEGFR. MlLTT4lv[XOnIHHzd4F6 NWq4dWdvhjFyMDFOwG0> Ml7FSG1UVw>? MXfpcohq[mm2czDFS2ZTKHS7cn;zbY5mKGurbnHz[UBi[3Srdnn0fS=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek85PzV{MUS1K|45PzV{MUS1QE9iRg>?
HPV 16-immortalized human keratinocytes NH3qbZBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmHIglUxKM7:TR?= MX\EUXNQ Mn3YbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86Ojh6N{iyK|46Ojh6N{iyQE9iRg>?
HPV 16-immortalized human keratinocytes MXLGeY5kfGmxbjDhd5NigQ>? NXvsd5BwhjVyIN88US=> MknuSG1UVw>? NFzNT21qdmS3Y3XzJIFzemW|dDDpckB1cGViQ3XscEBEgWOuZR?= M33sTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl{OEi3PFIoRjl{OEi3PFI9N2F-
HPV 16-immortalized human keratinocytes MnTqRZBweHSxc3nzJIF{e2G7 MXT+OVAh|ryP NFTpSndFVVOR NF36blhqdmS3Y3XzJIFxd3C2b4Ppd{4> MmKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTJ6OEe4Nkc,QTJ6OEe4Nlww[T5?
A431 NYjr[mp4U2mwYYPlJIF{e2G7 NVT0bGRyhjFyIN88US=> NXXnSmU3TE2VTx?= M3\sWYlvcGmkaYTzJJRp\SCkYYPhcEBidmRiVFfGMe6yNXO2aX31cIF1\WRidInyc5NqdmVicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBGT0[U MmTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB5MEKyOlIoRjFyN{CyNlYzRC:jPh?=
MDA-468  MY\LbY5ie2ViYYPzZZk> NF[3NZJ,OTBizszN NGHaZopFVVOR MmH5bY5pcWKrdIOgeIhmKGKjc3HsJIFv\CCWR1[t{tEue3SrbYXsZZRm\CC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hd2ZidHjlJGVITlJ? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODdyMkK2Nkc,OTB5MEKyOlI9N2F-
A431 NVu4flZjTnWwY4Tpc44h[XO|YYm= MlvoglExKM7:TR?= MnjySG1UVw>? NGLCZ|RqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 M4P4OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{CyNlYzLz5zMEewNlI3OjxxYU6=
MDA-MB-231 MX;LbY5ie2ViYYPzZZk> MWL+OUDPxE1? M2fXOGROW09? Mmi3bY5pcWKrdIOgSWdHKHO2aX31cIF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIF\LTHI> MorOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTFyM{CxOFYoRjFzMEOwNVQ3RC:jPh?=
CNE2 MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIrUenYyODBizszN M1f2RWROW09? NF3hUIlqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[nliOUiuOEU> NFWxfnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUSxNFMzOid-MUG0NVA{OjJ:L3G+
CNE2 NHHvWVRMcW6jc3WgZZN{[Xl? NHW3[2t,OTByIN88US=> MVnEUXNQ NFK5[o1qdmirYnn0d{BGT0[UIIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdg>? Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF2MUCzNlIoRjFzNEGwN|IzRC:jPh?=
CNE2 NHzl[ZBHfW6ldHnvckBie3OjeR?= NVL6VW9ohjFyMDFOwG0> MmS5SG1UVw>? M4TXdWlvcGmkaYTzJG1CWEtiYX7kJGFMXCCjY4TpeoF1cW:w MoHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF2MUCzNlIoRjFzNEGwN|IzRC:jPh?=
CNE2 M3yyOWZ2dmO2aX;uJIF{e2G7 MYj+OVAh|ryP Mnn1SG1UVw>? NG\RTmti\m[nY4TzJINmdGxiY4njcIUh\Gm|dILpZpV1cW:w NWXJOHRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0NVA{OjJpPkGxOFExOzJ{PD;hQi=>
HSC-2 M3mzTWtqdmG|ZTDhd5NigQ>? NXmyNGV{QMLizszN MXXEUXNQ MVXpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gSWdHWiCjbnSgRYt1 MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6OUK4OUc,OTd4OEmyPFU9N2F-
HSC-2 MlrORZBweHSxc3nzJIF{e2G7 NXS0SZVbQMLizszN MUnEUXNQ MkjabY5pcWKrdIOgSoF{NW2nZHnheIVlKGGyb4D0c5Nqew>? NUHYUHdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFkzQDVpPkG3Olg6Ojh3PD;hQi=>
HEp-2 M2X5[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NF7idnh,OTBizszN M3HYNmROW09? MYrlcohidmOnczDvdolld26rbj3pcoR2[2WmIHfyc5d1cC2rbnjpZol1d3K7 NFrNV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKwNlc1OSd-MkCyNFI4PDF:L3G+
SubG1 MlHJRZBweHSxc3nzJIF{e2G7 M3G2fp4yOCEQvF2= MmfCSG1UVw>? NITYSphmdmijbnPld{Bwemmmb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> Ml;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{MEK3OFEoRjJyMkCyO|QyRC:jPh?=
HEp-2 NUXFVm5sTnWwY4Tpc44h[XO|YYm= NYnDUJp{hjFyIN88US=> MWXEUXNQ NIPjTpdmdmijbnPld{BQemmmb37pck1qdmS3Y3XkJGJigCCjY4TpeoF1cW:wLDDCZ4wuOiCmZXfyZYRifGmxbjDhcoQhW0mUVEGgbY5i[3SrdnH0bY9v NHW3T|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKwNlc1OSd-MkCyNFI4PDF:L3G+
H508 M1LQVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4TTc54yKM7:TR?= M{njTmROW09? Mn\JcYl1cWejdHXzJGNRTi2vZXTpZZRm\CCKNUC4JINmdGxiZ4Lve5Rp NI\qTpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWxOFkzPCd-Mk[1NVQ6OjR:L3G+
A431 MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NWX3WlA6XGW|dHXkJIZweiCjboTpdJJwdGmoZYLheIl3\SCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMtKEmFNUC9NlDPxE1? M{TIb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlQzLz5zNUGwPVY1OjxxYU6=
HeLa M{fjWmZ2dmO2aX;uJIF{e2G7 MX2zNEBucW6| MWXJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJ\UyjIHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOzBibXnud{BxemmxcjD0c{BGT0Zic4TpcZVt[XSrb36gZpkhX2W|dHXyckBjdG:2dHnu[y=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzOECyPUc,OjF5MUiwNlk9N2F-
BT-37 MkO1dWhVWyCjc4PhfS=> NYXWXnhmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz NULlfVk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NFfJdIxyUFSVIHHzd4F6 MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NIrUWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NF;Zc5FyUFSVIHHzd4F6 MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NXXSdZQyeUiWUzDhd5NigQ>? NUXPSIFEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NYnCSmprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
HEK293 NVTDcGNNTnWwY4Tpc44h[XO|YYm= M{f4eVEhcHJ? MnTOTY5pcWKrdHnvckBw\iCqdX3hckBnfWyuIHzlcod1cCCSS13ZWFEh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{B2e2mwZzDFSnMhMDJ2NzD0c{AzPTlicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iaX3teY5w[XOjeTygT4k:OS56N988US=> M{K5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSxNVk{Lz5{OUm0NVE6OzxxYU6=
HEK293 NEXPNotHfW6ldHnvckBie3OjeR?= MVWxJIhz NHKz[lRKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHygcIVv\3SqIGDLUXlVOSCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHW|aX7nJGVHWyBqMkS3JJRwKDJ3OTDy[ZNq\HWnczmgZZMhe3Wkc4TyZZRmKGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDpcY12dm:jc3H5MEBKSzVyPUG5MlbPxE1? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MUG5N{c,Ojl7NEGxPVM9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / Neu / p-Tyr ; 

PubMed: 10931950     


MCF-10AyTE cells with or without AG-1478. After 24 h, cell lysates were prepared in EBC buffer and subjected to immunoblot procedures for EGFR, ErbB-2yNeu, and P-Tyr. Levels of a 180-kDa P-Tyr band, probably representing EGFR and ErbB-2yNeu, were reduced by AG-1478 without any change in receptor protein content.

Shc / PLC-γ1 ; 

PubMed: 10931950     


MCF-10AyTE cells with or without AG-1478. After 24 h, cell lysates were prepared in EBC buffer and subjected to immunoblot procedures for EGFR, ErbB-2yNeu, and P-Tyr. Levels of a 180-kDa P-Tyr band, probably representing EGFR and ErbB-2yNeu, were reduced by AG-1478 without any change in receptor protein content.

10931950
Growth inhibition assay
Cell viability ; 

PubMed: 25258648     


Dose-dependent effects of EGFR inhibitor AG-1478 on EGF-induced cell viability in OVCAR-3 cells. Cells were treated for 48 h with EGF (10 ng/mL) alone or in combination of AG-1478 (0, 0.25, 0.5 and 1 µmol/L). A cell viability assay was performed using MTT and values were normalized to untreated controls (no EGF, no inhibitors). Blackened bars were EGF treated. *, ** indicate a significant increase (p≤0.05) and # indicates a significant decrease (p≤0.05) between groups by ANOVA and Tukey’s pairwise comparisons. Experiments were performed in triplicate and all data are shown as mean ± SEM.

25258648
体内研究 AG-1478给药阻断肿瘤位点的EGFR磷酸化,并抑制过表达wt EGFR 的A431异种移植物和表达de2-7 EGFR的胶质瘤异种移植物的生长。甚至不足治疗剂量的AG-1478也能够显著增强细胞毒性药物的效能,结合AG-1478和temozolomide对人胶质瘤异种移植物表现出协同的抗肿瘤活性。AG-1478结合抗-EGFR抗体(mAb 806)对过表达EGFR的肿瘤异种移植物表现出额外的,在某些情况下协同的抗肿瘤活性。[4] AG-1478 (0.4 mg)结合单剂量25 μCi 90Y-CHX-A''-DTPA-hu3S193,与单独药物相比,会使疗效显著增强。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[2]

- 合并
  • Cell lines: U87MG
  • Concentrations: 溶解于DMSO,终浓度为~100 μM
  • Incubation Time: 72小时
  • Method: 将细胞在96孔板中不同浓度的AG-1478下暴露72小时。AG-1478对细胞生长的作用使用Alamar Blue实验检测。将20μL等份Alamar Blue加入到每孔中,其吸光度使用Spectromax Scanning Micro酶标仪测定。AG-1478的作用表示为生长抑制的百分比,使用未处理细胞作为对照组(0% 抑制)。细胞内DNA合成使用[3H] 胸苷整合法测定。
    (Only for Reference)
动物实验:

[4]

- 合并
  • Animal Models: 皮下移植 A431 或 U87MG.Δ2-7 肿瘤细胞的雌性 BALB/c nu/nu 小鼠
  • Dosages: ~1 mg/kg
  • Administration: 每周腹腔注射3次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 25 mg/mL (79.17 mM)
Water Insoluble
Ethanol ''13 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 315.75
化学式

C16H14ClN3O2

CAS号 153436-53-4
储存条件 粉状
溶于溶剂
别名 NSC 693255

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

相关EGFR产品

Tags: 购买AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478)供应商 | 采购AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478)价格 | AG-1478 (Tyrphostin AG-1478)生产 | 订购AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID